Patients with advanced stage small cell lung cancer may have a chance of living longer, thanks to a treatment that combines chemotherapy with immunotherapy, which was shown in a study to reduce the risk of death by 30 per cent.
It is the first breakthrough in treating the aggressive disease in more than 20 years, says medical director of biotechnology company Roche Singapore, Dr Sivabalan Sivanesan.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
